We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where ...

D. Boral Capital reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. D. Boral Capital ...

We recently compiled a list of the 10 Firms Shine Amid Wall Street’s Lackluster Trading. In this article, we are going to ...

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

ImmunityBio, Inc. (NASDAQ:IBRX) released progress in its ongoing FDA discussions regarding three areas of its clinical ...

ImmunityBio also said it will submit a regulatory filing for an alternative source of Bacillus Calmette-Guerin, a drug which treats bladder cancer. The company expects to produce large quantities of ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced significant progress in its ongoing ...

ImmunityBio is at the forefront of developing innovative immunotherapies and cell therapies. The company has a vertically integrated approach, allowing it to oversee every step of development, from ...

ImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) hit a new 52-week low during trading on Friday . The company traded as low ...

BTIG analyst Justin Zelin initiated coverage of ImmunityBio (IBRX) with a Buy rating and $6 price target Lead product Anktiva is approved in ...

Investing.com -- 免疫疗法公司ImmunityBio的股价上涨高达20%，创下自10月28日以来最大单日涨幅。 股价飙升是在该公司宣布与FDA的持续讨论取得重大进展之后。这些讨论涉及ImmunityBio在非肌层浸润性膀胱癌（NMIBC）和非小细胞肺癌（NSCLC）临床开发管线的三个领域。